(From: scopus.com ; update: 18/12/2020)
Phanthaphol N, Somboonpatarakun C, Suwanchiwasiri K, Cheiochansin T, Wongkham S, Maher J, Sujjitjoon J, Junking M, Yenchitsomanus P. (2021). Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells. Front. Oncol. 2021. doi: 10.3389/fonc.2021.657868
Supimon K, Sangsuwannukul T, Sujjitjoon J, Phanthaphol N, Chieochansin T, Poungvarin N, Junking M, Maher J, Yenchitsomanus P. (2021). Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma. Scientific Reports. 2021. 11(1): p. 6276.
Sangsuwannukul T, Supimon K, Sujjitjoon J, Phanthaphol N, Chieochansin T, Poungvarin N, Junking M, Yenchitsomanus P. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells. Int Immunopharmacol. 2020;89(PtB):107069. doi: 10.1016/j.intimp.2020.107069.
Panya A, Thepmalee C, Sawasdee N, Sujjitjoon J, Phanthaphol N, Junking M, Yenchitsomanus P-T. (2018). Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells. Cancer Immunol Immunother. 2018;67(10):1579-1588. doi:10.1007/s00262-018-2212-2